Oryzon Genomics (ORY) Q1 2026 earnings summary

Executive summary

• Reported strong clinical progress in both oncology/hematology and CNS franchises, with positive data from iadademstat in AML and ongoing expansion into new indications.

• Preparing for FDA protocol resubmission for the PORTICO-2 Phase III trial with vafidemstat in BPD aggression, and advancing programs in schizophrenia and autism spectrum disorder.

• Strengthened intellectual property protection for both iadademstat and vafidemstat, with new patents granted in multiple jurisdictions.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $25.4 million as of March 31, 2026.

• R&D expenses increased to $5.2 million in Q1 2026 from $2.6 million in Q1 2025.

• General and administrative expenses rose to $1.5 million from $1.2 million year-over-year.

• Net loss was $2.0 million for Q1 2026, compared to $1.6 million in Q1 2025.

• Negative net result was $1.4 million (-$0.02 per share) for Q1 2026, versus $1.8 million (-$0.03 per share) in Q1 2025.

Outlook and guidance

• Anticipates presenting updated clinical data at EHA 2026, with further expansion of iadademstat into pivotal trials and new indications.

• Expects initial clinical updates from the RESTORE trial in sickle cell disease by year-end.

• Preparing for Phase III PORTICO-2 protocol resubmission and further CNS trial initiations.